Up-regulation of p27kip1 contributes to Nrf2-mediated protection against angiotensin II-induced cardiac hypertrophy

Cardiovascular Research

Volumn 90, Issue 2, 2011, Pages 315-324

  Li, Jinqing ^a   Zhang, Cheng ^b   Xing, Yifan ^a,b   Janicki, Joseph S ^a   Yamamoto, Masayuki ^c   Wang, Xing Li ^b   Tang, Dong Qi ^d   Cui, Taixing ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b SHANDONG UNIVERSITY   (China)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Angiotensin II; Cardiac hypertrophy; Nrf2; Oxidative stress; p27kip1

Indexed keywords

ADENOVIRUS VECTOR; ANGIOTENSIN II; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR NRF2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; GENE INDUCTION; GENE OVEREXPRESSION; HEART MUSCLE; HEART MUSCLE CELL; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; KNOCKOUT MOUSE; MALE; MOUSE; NEWBORN; NONHUMAN; OSMOTIC MINIPUMP; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; TRANSCRIPTION REGULATION; UPREGULATION; WILD TYPE;

ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; CARDIOMEGALY; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEEDBACK, PHYSIOLOGICAL; MALE; MICE; MYOCYTES, CARDIAC; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; PHENOLS; PLANT EXTRACTS; RATS; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA, SMALL INTERFERING; UP-REGULATION; VASOCONSTRICTOR AGENTS;

EID: 79955418633     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvr010     Document Type: Article

References (40)

1. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000;52:415-472.
2. Dzau VJ. Circulating versus local renin-angiotensin system in cardiovascular homeo-stasis. Circulation 1988;77:I4-I13.
3. Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens Suppl 2005;23:S9-S17.
4. Prisant LM. Management of hypertension in patients with cardiac disease: use of renin-angiotensin blocking agents. Am J Med 2008;121:S8-S15. (Pubitemid 351970086)
5. Werner C, Baumhakel M, Teo KK, Schmieder R, Mann J, Unger T et al. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin Res Cardiol 2008;97:418-431.
6. Steckelings UM, Artuc M, Wollschlager T, Wiehstutz S, Henz BM. Angiotensin-converting enzyme inhibitors as inducers of adverse cutaneous reactions. Acta Derm Venereol 2001;81:321-325. (Pubitemid 34015484)
7. Schluter KD, Wenzel S. Angiotensin II: a hormone involved in and contributing to pro-hypertrophic cardiac networks and target of anti-hypertrophic cross-talks. Phar-macol Ther 2008;119:311-325.
8. Das DK, Maulik N, Engelman RM. Redox regulation of angiotensin II signaling in the heart. J Cell Mol Med 2004;8:144-152. (Pubitemid 44145533)
9. Sabri A, Hughie HH, Lucchesi PA. Regulation of hypertrophic and apoptotic signaling pathways by reactive oxygen species in cardiac myocytes. Antioxid Redox Signal 2003;5: 731-740. (Pubitemid 37462056)
10. Hu CM, Chen YH, Chiang MT, Chau LY. Heme oxygenase-1 inhibits angiotensin II-induced cardiac hypertrophy in vitro and in vivo. Circulation 2004;110:309-316.
11. Widder JD, Fraccarollo D, Galuppo P, Hansen JM, Jones DP, Ertl G et al. Attenuation of angiotensin II-induced vascular dysfunction and hypertension by overexpression of Thioredoxin 2. Hypertension 2009;54:338-344.
12. Jialal I, Devaraj S. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 2000;342:1917-1918. (Pubitemid 30419061)
13. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:23-33.
14. Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized con-trolled trial. JAMA 2005;293:1338-1347. (Pubitemid 40381486)
15. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mor-tality. Ann Intern Med 2005;142:37-46.
16. Li J, Ichikawa T, Janicki JS, Cui T. Targeting the Nrf2 pathway against cardiovascular disease. Expert Opin Ther Targets 2009;13:785-794.
17. Li J, Ichikawa T, Villacorta L, Janicki JS, Brower GL, Yamamoto M et al. Nrf2 protects against maladaptive cardiac responses to hemodynamic stress. Arterioscler Thromb Vasc Biol 2009;29:1843-1850.
18. He X, Kan H, Cai L, Ma Q. Nrf2 is critical in defense against high glucose-induced oxi-dative damage in cardiomyocytes. J Mol Cell Cardiol 2009;46:47-58.
19. Dreger H, Westphal K, Weller A, Baumann G, Stangl V, Meiners S et al. Nrf2-dependent upregulation of antioxidative enzymes: a novel pathway for protea-some inhibitor-mediated cardioprotection. Cardiovasc Res 2009;83:354-361.
20. Rothe G, Valet G. Flow cytometric analysis of respiratory burst activity in phagocytes with hydroethidine and 2', 7'-dichlorofluorescin. J Leukoc Biol 1990;47:440-448. (Pubitemid 20155877)
21. Gagnon C, Leblond FA, Filep JG. Peroxynitrite production by human neutrophils, monocytes and lymphocytes challenged with lipopolysaccharide. FEBS Lett 1998; 431:107-110. (Pubitemid 28330862)
22. Ohba M, Shibanuma M, Kuroki T, Nose K. Production of hydrogen peroxide by trans-forming growth factor-beta 1 and its involvement in induction of egr-1 in mouse osteoblastic cells. J Cell Biol 1994;126:1079-1088. (Pubitemid 24252152)
23. Wu S, Gao J, Ohlemeyer C, Roos D, Niessen H, Kottgen E et al. Activation of AP-1 through reactive oxygen species by angiotensin II in rat cardiomyocytes. Free Radic Biol Med 2005;39:1601-1610. (Pubitemid 41642591)
24. Nakamura K, Fushimi K, Kouchi H, Mihara K, Miyazaki M, Ohe T et al. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation 1998;98:794-799. (Pubitemid 28391845)
25. Villacorta L, Zhang J, Garcia-Barrio MT, Chen XL, Freeman BA, Chen YE et al. Nitro-linoleic acid inhibits vascular smooth muscle cell proliferation via the Keap1/Nrf2 sig-naling pathway. Am J Physiol Heart Circ Physiol 2007;293:H770-H776. (Pubitemid 47105140)
26. Hauck L, Harms C, An J, Rohne J, Gertz K, Dietz R et al. Protein kinase CK2 links extracellular growth factor signaling with the control of p27(Kip1) stability in the heart. Nat Med 2008;14:315-324. (Pubitemid 351347917)
27. Hu Y, Wang X, Zeng L, Cai DY, Sabapathy K, Goff SP et al. ERK phosphorylates p66shcA on Ser36 and subsequently regulates p27kip1 expression via the Akt-FOXO3a pathway: implication of p27kip1 in cell response to oxidative stress. Mol Biol Cell 2005;16:3705-3718. (Pubitemid 41077080)
28. van Gorp AG, Pomeranz KM, Birkenkamp KU, Hui RC, Lam EW, Coffer PJ. Chronic protein kinase B (PKB/c-akt) activation leads to apoptosis induced by oxidative stress-mediated Foxo3a transcriptional up-regulation. Cancer Res 2006;66:10760-10769. (Pubitemid 44876971)
29. Lee YJ, Lee JH, Han HJ. Extracellular adenosine triphosphate protects oxidative stress-induced increaseofp21(WAF1/Cip1) and p27(Kip1) expression in primarycul-tured renal proximal tubule cells: role of PI3K and Akt signaling. J Cell Physiol 2006; 209:802-810. (Pubitemid 44665702)
30. Tamamori-Adachi M, Hayashida K, Nobori K, Omizu C, Yamada K, Sakamoto N et al. Down-regulation of p27Kip1 promotes cell proliferation of rat neonatal cardiomyo-cytes induced by nuclear expression ofcyclin D1 and CDK4. Evidence for impaired Skp2-dependent degradation of p27 in terminal differentiation. J Biol Chem 2004; 279:50429-50436. (Pubitemid 39577861)
31. Ikeda Y, Aihara K, Sato T, Akaike M, Yoshizumi M, Suzaki Y et al. Androgen receptor gene knockout male mice exhibit impaired cardiac growth and exacerbation of angio-tensin II-induced cardiac fibrosis. J Biol Chem 2005;280:29661-29666. (Pubitemid 41177042)
32. Freund C, Schmidt-Ullrich R, Baurand A, Dunger S, Schneider W, Loser P et al Requirement of nuclear factor-kappaB in angiotensin II-and isoproterenol-induced cardiac hypertrophy in vivo. Circulation 2005;111:2319-2325. (Pubitemid 40647067)
33. Li J, Ichikawa T, Jin Y, Hofseth LJ, Nagarkatti P, Nagarkatti M et al. An essential role of Nrf2 in American ginseng-mediated anti-oxidative actions in cardiomyocytes. J Ethnopharmacol 2010;130:222-230.
34. Briones AM, Touyz RM. Oxidative stress and hypertension: current concepts. Curr Hypertens Rep 2010;12:135-142.
35. Sawyer DB, Siwik DA, Xiao L, Pimentel DR, Singh K, Colucci WS. Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 2002;34:379-388. (Pubitemid 37163454)
36. Piao CS, Gao S, Lee GH, Kim DS, Park BH, Chae SW et al. Sulforaphane protects ischemic injury of hearts through antioxidant pathway and mitochondrial K(ATP) channels. Pharmacol Res 2010;61:342-348.
37. Sussan TE, Rangasamy T, Blake DJ, Malhotra D, El-Haddad H, Bedja D et al. Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice. Proc Natl Acad Sci USA 2009;106: 250-255.
38. Ichikawa T, Li J, Meyer CJ, Janicki JS, Hannink M, Cui T. Dihydro-CDDO-trifluoroethyl amide (dh404), a novel Nrf2 activator, suppresses oxidative stress in cardiomyocytes. PLoS One 2009;4:e8391.
39. Cho MK, Kim WD, Ki SH, Hwang JI, Choi S, Lee CH et al. Role of Galpha12 and Galpha13 as novel switches for the activity of Nrf2, a key antioxidative transcription factor. Mol Cell Biol 2007;27:6195-6208. (Pubitemid 47326706)
40. Nishida M, Tanabe S, Maruyama Y, Mangmool S, Urayama K, Nagamatsu Y et al. G alpha 12/13-and reactive oxygen species-dependent activation ofc-Jun NH2-terminal kinase and p38 mitogen-activated protein kinase by angiotensin receptor stimulation in rat neonatal cardiomyocytes. J Biol Chem 2005;280:18434-18441. (Pubitemid 41389093)